__NUXT_JSONP__("/drugs/Tremelimumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"745013-59-6",chebiId:b,chemicalFormula:b,definition:"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.",fdaUniiCode:"QEN1X95CIX",identifier:"C49085",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C128036"],synonyms:["Anti-CTLA4 Human Monoclonal Antibody CP-675,206","CP-675","CP-675,206","CP-675206","Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer","TREMELIMUMAB","Ticilimumab",a,"ticilimumab"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTremelimumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Tremelimumab","","2021-10-30T13:40:22.443Z")));